Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Patients with Previously Untreated Mantle Cell Lymphoma

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeTrial IDs
Phase IIBiomarker/Laboratory analysis, Supportive care, TreatmentActive60 and overE1411
NCI-2011-02980, CDR0000707057, ECOG-E1411, NCT01415752

Trial Description

Summary

This randomized phase II trial studies how well rituximab, bendamustine hydrochloride, and bortezomib followed by rituximab and lenalidomide works in treating patients with previously untreated mantle cell lymphoma. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as bendamustine hydrochloride, also work in different ways to kill cancer cells, by stopping them from dividing, or by stopping them from spreading. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of mantle cell lymphoma by blocking blood flow to the cancer. It is not yet known whether giving rituximab with bendamustine hydrochloride and bortezomib is more effective than rituximab and bendamustine hydrochloride, followed by rituximab alone or with lenalidomide in treating mantle cell lymphoma.

Further Study Information

PRIMARY OBJECTIVES:

I. To determine whether the addition of bortezomib (RBV) to an induction regimen of rituximab-bendamustine (bendamustine hydrochloride) (RB) improves progression-free survival (PFS) compared to RB alone in patients with previously untreated mantle cell lymphoma.

II. To determine whether the addition of lenalidomide to a consolidation regimen of rituximab following an induction regimen of RB or RBV improves PFS compared to consolidation rituximab alone in this patient population.

SECONDARY OBJECTIVES:

I. To determine whether the addition of bortezomib to induction therapy improves the positron emission tomography (PET)-documented complete response rate compared to RB alone.

II. To determine the objective response rate (ORR) for RB and RBV.

III. Among patients who do not have PET-documented complete response (CR) at the end of induction, to determine whether the addition of lenalidomide to consolidation therapy improves CR and ORR compared with rituximab alone.

IV. To determine overall survival (OS) in the treatment arms.

V. To determine safety, with attention to the addition of bortezomib in the induction regimen and lenalidomide-rituximab as consolidation therapy.

TERTIARY OBJECTIVES:

I. To collect paraffin embedded tissue for creation of tissue microarray.

II. To collect and bank serum and blood mononuclear cells for future studies.

III. To collect formalin-fixed paraffin-embedded (FFPE) tissue to analyze potential prognostic factors: Ki-67 antigen (Ki-67) proliferation index by immunohistochemistry and correlation with proposed 5-gene set of proliferation markers analyzed by ribonucleic acid (RNA) polymerase chain reaction (PCR); SRY (sex determining region Y)-box 11 (SOX 11) expression by immunohistochemistry; and micro-RNA levels by microarray.

IV. Using patient-reported outcomes data, to determine the extent and severity of neuropathy associated with the addition of bortezomib to induction treatment.

V. Using patient-reported outcomes data, to determine the extent and severity of fatigue associated with the addition of lenalidomide to consolidation treatment.

VI. To evaluate the effects of the addition of bortezomib and lenalidomide on patient-reported health-related quality of life.

VII. To evaluate the effects of bortezomib-related neuropathy on patient-reported health-related quality of life.

VIII. To evaluate the response of lymphoma-specific symptoms to treatment.

IX. Using longitudinal patient-reported outcomes data, to describe the trajectory of lymphoma symptoms, neuropathy, fatigue, and overall health-related quality of life prior to, during, and following treatment among older adults with mantle cell lymphoma (MCL).

X. To assess the proportion of patients up and down staging when fludeoxyglucose F 18- (FDG) PET/computed tomography (CT) is added to standard Ann Arbor staging.

XI. To assess the ability of pre-treatment FDG-PET/CT semi quantitative parameters including maximum standardized uptake value (SUVmax) and metabolic measurements to predict response rate and PFS.

XII. Among patients with interim FDG-PET/CT imaging, to assess the correlation of interim FDG-PET/CT imaging with response rate and PFS both during induction and consolidation therapy.

XIII. To assess standard FDG-PET/CT metrics including SUVmax, tumor metabolic burden, total tumor burden, and association with pathology features (blastoid variant vs. other, and Ki67) in the setting of MCL.

XIV. To assess differences in overall and complete response rates when using Deauville vs International Harmonization Project FDG-PET/CT interpretation criteria.

XV. To determine whether there is a correlation between FDG-PET/CT response and residual disease assessment by molecular and/or flow cytometric techniques.

XVI. To determine whether the number of malignant cells in circulation predict the number of cells in marrow.

XVII. To determine whether the number of malignant cells in circulation/in marrow at the end of induction correlate with CR and 2-year PFS.

XVIII. To determine whether there is a higher rate of minimal residual disease (MRD) negativity among patients randomized to RBV as compared with RB, and among patients treated with lenalidomide-rituximab (LR) maintenance compared with rituximab (R).

XIX. To compare the two methods of MRD detection - molecular techniques and flow cytometry as prognostic markers for outcome.

OUTLINE:

STEP 1: Patients are randomized to 1 of 4 treatment arms.

ARM A: Patients receive induction therapy comprising rituximab intravenously (IV) on day 1 and bendamustine hydrochloride IV over 60 minutes on days 1-2. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

ARM B: Patients receive induction therapy comprising bortezomib subcutaneously (SC) or IV on days 1 and 8, and rituximab and bendamustine hydrochloride as in Arm A. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

ARM C: Patients receive induction therapy comprising rituximab and bendamustine hydrochloride as patients in Arm A. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

ARM D: Patients receive bortezomib, rituximab, and bendamustine hydrochloride as in arm B. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

STEP 2: Patients with improved response or no interval change in their tumor measurements with restaging from courses 3 to 6 in Step 1 are assigned to 1 of 4 arms.

ARM E (after Arm A): Patients receive consolidation therapy comprising rituximab IV on day 1. Treatment repeats every 8 weeks for 12 doses in the absence of disease progression or unacceptable toxicity.

ARM F (after Arm B): Patients receive consolidation therapy comprising rituximab IV on day 1 as in Arm E. Treatment repeats every 8 weeks for 12 doses in the absence of disease progression or unacceptable toxicity.

ARM G (after Arm C): Patients receive consolidation therapy comprising lenalidomide orally (PO) daily on days 1-21 every 28 days for 24 courses and rituximab IV every 8 weeks for 12 doses in the absence of disease progression or unacceptable toxicity.

ARM H (after Arm D): Patients receive consolidation therapy comprising lenalidomide PO daily on days 1-21 every 28 days for 24 courses and rituximab IV every 8 weeks for 12 doses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2.5 years, every 6 months for 8 years, and then annually for 5 years.

Eligibility Criteria

Inclusion Criteria:

STEP 1 REGISTRATION:

Mantle cell lymphoma International Prognostic Index (IPI) (MIPI) score must be calculated and entered in Oncology Patient Enrollment Network (OPEN)

NOTE: for this calculation white blood cell (WBC) 7,500/mm^3 = 7,500/uL = 7.5 x 10^9/L should be entered as 7500

Females of childbearing potential must not be pregnant or breast feeding;

All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy

A female of childbearing potential (FCBP) is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)

Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception

Patients must have measurable disease

Histologically confirmed untreated mantle cell lymphoma, with documented cyclin D1 (BCL1) by immunohistochemical stains and/or t(11;14) by cytogenetics or fluorescent in situ hybridization (FISH)

Patients must have at least one objective measurable disease parameter; baseline measurements and evaluations must be obtained within 4 weeks of registration to the study; abnormal PET scans will not constitute evaluable disease, unless verified by CT scan or other appropriate imaging; measurable disease in the liver is required if the liver is the only site of lymphoma; if the only radiographically assessable disease is splenomegaly (without discrete measurable nodules), the patient can be enrolled, but for such patients CR cannot be differentiated from PR, while the spleen will be considered nodal with respect to criteria for progressive disease (PD)

Eastern Cooperative Oncology Group (ECOG) performance status between 0-2

Absolute neutrophil count (ANC) >= 1,500/mm^3 (1.5 x 10^9/L) (unless due to marrow involvement) obtained within 4 weeks prior to registration

Platelets >= 100,000/mm^3 (100 x 10^9/L) (unless due to marrow involvement) obtained within 4 weeks prior to registration

Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 x upper limit of normal (ULN) obtained within 4 weeks prior to registration

Total bilirubin =< 2 x upper limit of normal (ULN) or, if total elevated, direct bilirubin =< 2 x upper limit of normal (ULN) obtained within 4 weeks prior to registration

Calculated creatinine clearance by Cockroft-Gault formula >= 30 mL/min obtained within 4 weeks prior to registration

No evidence of prior malignancy except: adequately treated non-melanoma skin cancer, adequately treated in situ carcinoma, low grade prostate carcinoma (Gleason grade =< 6) managed with observation that has been stable for at least 6 months, or any malignancy treated with curative intent continuously disease free for >= 3 years so as not to interfere with interpretation of radiographic response

No prior therapy for MCL, except: < 2 weeks of steroid therapy for symptom control or local radiation therapy for symptom control if there is measurable disease outside the radiation portal; patients may be on chronic steroids for non-malignant disease if on a stable dose equivalent to =< 20 mg prednisone per day

Patient must have no known central nervous system (CNS) involvement

Patient agrees that if randomized to Arms C or D, and proceeding onto Arms G or H, they must register into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist

Patients must have no medical contra-indications to, and be willing to take, deep vein thrombosis (DVT) prophylaxis as all patients registering to the lenalidomide/rituximab Arms G and H will be required to have deep vein thrombosis (DVT) prophylaxis; patients randomized to Arms G or H who have a history of a thrombotic vascular event will be required to have full anticoagulation, therapeutic doses of low-molecular weight heparin or warfarin to maintain an international normalized ratio (INR) between 2.0-3.0, or any other accepted full anticoagulation regimen (e.g., direct thrombin inhibitors or factor Xa inhibitors) with appropriate monitoring for that agent; patients on Arms G and H without a history of a thromboembolic event are required to take a daily aspirin (81 mg or 325 mg) for DVT prophylaxis; patients who are unable to tolerate aspirin should receive low molecular weight heparin therapy or warfarin treatment or another accepted full anticoagulation regimen

Ways to minimize risk of DVT should be discussed with patients, including, but not limited to, avoiding smoking, minimizing pro-thrombotic hormone replacement, avoiding prolonged periods of inactivity (e.g. uninterrupted long car or plane trips)

Human immunodeficiency virus (HIV)-positive patients are not excluded but, to enroll, must meet all of the below criteria:

HIV is sensitive to antiretroviral therapy

Must be willing to take effective antiretroviral therapy, if indicated

Cluster of differentiation (CD)4 count at screening >= 300 cells/mm^3

No history of acquired immunodeficiency syndrome (AIDS)-defining conditions

If on antiretroviral therapy, must not be taking zidovudine or stavudine

Must be willing to take prophylaxis for pneumocystis jiroveci pneumonia (PCP) during therapy and until at least 2 months following the completion of therapy or until the CD4 cells recover to over 250 cells/mm^3, whichever occurs later

Patients must not have grade 2 or greater peripheral neuropathy

Patients must not have New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia

Patients must not have hypersensitivity to bortezomib, boron or mannitol

Patients must not have a serious medical or psychiatric illness likely to interfere with study participation

Patients must not be participating in any other therapeutic clinical trial or taking any other experimental medications within 14 days prior to registration

STEP 2 REGISTRATION:

ECOG performance status between 0-2

CR, partial response (PR) or stable disease (SD) after Step 1

ANC >= 1000 cells/mm^3 (1.0 x 10^9/L)

Platelets >= 75,000 cells/mm^3 (75 x 10^9/L)

AST/ALT =< 2 x upper limit of normal (ULN)

Total bilirubin =< 2 x upper limit of normal (ULN) or, if total elevated, direct bilirubin =< 2 x upper limit of normal (ULN)

Calculated creatinine clearance by Cockroft-Gault formula >= 30 ml/min

Patient agrees that if randomized to Arms C or D, and proceeding onto Arms G or H, they must register into the mandatory Risk Evaluation and Mitigation Strategies (REMS) program, and be willing and able to comply with the requirements of Rems

Pregnancy tests must occur within 10-14 days and again within 24 hours prior to initiation of cycle 1 of lenalidomide; females of childbearing potential (FCBP) with regular or no menstruation must have a pregnancy test weekly for the first 28 days and then every 28 days while on lenalidomide therapy (including breaks in therapy); at discontinuation of lenalidomide and at day 28 post the last dose of lenalidomide; females with irregular menstruation must have a pregnancy test weekly for the first 28 days and then every 14 days while on lenalidomide therapy (including breaks in therapy), at discontinuation of lenalidomide and at day 14 and day 28 post the last dose of lenalidomide

Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10-14 days and again within 24 hours prior to starting cycle 1 of lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide; FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy, all patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure

A female of childbearing potential is any sexually mature female, regardless of sexual orientation of whether they have undergone tubal ligation, who meets the following criteria: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)

Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study/lenalidomide: for at least 28 days before starting lenalidomide; while participating in the study including interruptions in therapy; and for at least 28 days after discontinuation/stopping lenalidomide; the two methods of reliable contraception must include one highly effective method (i.e. intrauterine device (IUD), hormonal (birth control pills, injections, or implants, tubal ligation, partner’s vasectomy) and one additional effective (barrier) method (i.e. latex condom, diaphragm, cervical cap); FCBP must be referred to a qualified provider of contraceptive methods if needed

Women must agree to abstain from donating blood during study participation and for at least 28 days after discontinuation from protocol treatment

Males must agree to abstain from donating blood, semen, or sperm during study participation and for at least 28 days after discontinuation from protocol treatment

All males, regardless of whether they have undergone a successful vasectomy, must agree to use a latex condom during sexual contact with a female of childbearing potential, or to practice complete abstinence from heterosexual intercourse with any female of childbearing potential during all cycles of study treatment and for at least 28 days following discontinuation of protocol treatment

Patients must have no medical contra-indications to, and be willing to take, DVT prophylaxis as all patients registering to the lenalidomide/rituximab Arms G and H will be required to have deep vein thrombosis (DVT) prophylaxis; patients randomized to Arms G or H who have full anticoagulation, a history of a thrombotic vascular event will be required to have therapeutic doses of low molecular weight heparin or warfarin to maintain an INR between 2.0 – 3.0, or any other accepted full anticoagulation regimen (e.g., direct thrombin inhibitors or factor Xa inhibitors) with appropriate monitoring for that agent; patients on Arms G and H without a history of a thromboembolic event are required to take a daily aspirin (81 mg or 325 mg) for DVT prophylaxis; patients who are unable to tolerate aspirin should receive low molecular weight heparin therapy or warfarin treatment or another accepted full anticoagulation regimen

Ways to minimize risk of DVT should be discussed with patients, including, but not limited to, avoiding smoking, minimizing pro-thrombotic hormone replacement, avoiding prolonged periods of inactivity (e.g uninterrupted long car or plane trips)

Trial Contact Information

Trial Lead Organizations / Sponsors / Collaborators

ECOG-ACRIN Cancer Research Group

  • National Cancer Institute
Mitchell Reed Smith, Principal Investigator

Trial Sites

U.S.A.

Arkansas
Hot Springs

Mercy Cancer Center-Hot Springs

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Colorado
Colorado Springs

Penrose-Saint Francis Healthcare

Keren Sturtz
Ph: 303-777-2663
Email: kgeisen@co-cancerresearch.org

Keren Sturtz
Principal Investigator

Denver

Colorado Cancer Research Program NCORP

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Porter Adventist Hospital

Keren Sturtz
Ph: 303-777-2663
Email: kgeisen@co-cancerresearch.org

Keren Sturtz
Principal Investigator

Durango

Mercy Medical Center

Keren Sturtz
Ph: 303-777-2663
Email: kgeisen@co-cancerresearch.org

Keren Sturtz
Principal Investigator

Southwest Oncology PC

Keren Sturtz
Ph: 303-777-2663
Email: kgeisen@co-cancerresearch.org

Keren Sturtz
Principal Investigator

Littleton

Littleton Adventist Hospital

Keren Sturtz
Ph: 303-777-2663
Email: kgeisen@co-cancerresearch.org

Keren Sturtz
Principal Investigator

Longmont

Longmont United Hospital

Keren Sturtz
Ph: 303-777-2663
Email: kgeisen@co-cancerresearch.org

Keren Sturtz
Principal Investigator

Parker

Parker Adventist Hospital

Keren Sturtz
Ph: 303-777-2663
Email: kgeisen@co-cancerresearch.org

Keren Sturtz
Principal Investigator

Pueblo

Saint Mary Corwin Medical Center

Keren Sturtz
Ph: 303-777-2663
Email: kgeisen@co-cancerresearch.org

Keren Sturtz
Principal Investigator

Connecticut
Hartford

Smilow Cancer Hospital Care Center at Saint Francis

Adam M. Boruchov
Ph: 860-714-4680
Email: aborucho@stfranciscare.org

Adam M. Boruchov
Principal Investigator

New Haven

Yale University

Adam M. Boruchov
Ph: 860-714-4680
Email: aborucho@stfranciscare.org

Adam M. Boruchov
Principal Investigator

Delaware
Lewes

Beebe Medical Center

Gregory Andrew Masters
Ph: 302-733-6227
Email: gmasters@cbg.org

Gregory Andrew Masters
Principal Investigator

Newark

Christiana Care Health System-Christiana Hospital

Gregory Andrew Masters
Ph: 302-733-6227
Email: gmasters@cbg.org

Gregory Andrew Masters
Principal Investigator

Delaware Clinical and Laboratory Physicians PA

Gregory Andrew Masters
Ph: 302-733-6227
Email: gmasters@cbg.org

Gregory Andrew Masters
Principal Investigator

Helen F Graham Cancer Center

Gregory Andrew Masters
Ph: 302-733-6227
Email: gmasters@cbg.org

Gregory Andrew Masters
Principal Investigator

Medical Oncology Hematology Consultants PA

Gregory Andrew Masters
Ph: 302-733-6227
Email: gmasters@cbg.org

Gregory Andrew Masters
Principal Investigator

Regional Hematology and Oncology PA

Gregory Andrew Masters
Ph: 302-733-6227
Email: gmasters@cbg.org

Gregory Andrew Masters
Principal Investigator

Rehoboth Beach

Beebe Health Campus

Gregory Andrew Masters
Ph: 302-733-6227
Email: gmasters@cbg.org

Gregory Andrew Masters
Principal Investigator

Seaford

Nanticoke Memorial Hospital

Gregory Andrew Masters
Ph: 302-733-6227
Email: gmasters@cbg.org

Gregory Andrew Masters
Principal Investigator

Wilmington

Christiana Care Health System-Wilmington Hospital

Gregory Andrew Masters
Ph: 302-733-6227
Email: gmasters@cbg.org

Gregory Andrew Masters
Principal Investigator

Hawaii
Aiea

Oncare Hawaii Inc-Pali Momi

Jeffrey L. Berenberg
Ph: 808-586-2979
Email: Jeffrey.l.Berenberg.civ@mail.mil

Jeffrey L. Berenberg
Principal Investigator

Pali Momi Medical Center

Jeffrey L. Berenberg
Ph: 808-586-2979
Email: Jeffrey.l.Berenberg.civ@mail.mil

Jeffrey L. Berenberg
Principal Investigator

Honolulu

Kapiolani Medical Center for Women and Children

Jeffrey L. Berenberg
Ph: 808-586-2979
Email: Jeffrey.l.Berenberg.civ@mail.mil

Jeffrey L. Berenberg
Principal Investigator

Oncare Hawaii Inc-POB II

Jeffrey L. Berenberg
Ph: 808-586-2979
Email: Jeffrey.l.Berenberg.civ@mail.mil

Jeffrey L. Berenberg
Principal Investigator

OnCare Hawaii-Kuakini

Jeffrey L. Berenberg
Ph: 808-586-2979
Email: Jeffrey.l.Berenberg.civ@mail.mil

Jeffrey L. Berenberg
Principal Investigator

OnCare Hawaii-Liliha

Jeffrey L. Berenberg
Ph: 808-586-2979
Email: Jeffrey.l.Berenberg.civ@mail.mil

Jeffrey L. Berenberg
Principal Investigator

Queen's Medical Center

Jeffrey L. Berenberg
Ph: 808-586-2979
Email: Jeffrey.l.Berenberg.civ@mail.mil

Jeffrey L. Berenberg
Principal Investigator

Straub Clinic and Hospital

Jeffrey L. Berenberg
Ph: 808-586-2979
Email: Jeffrey.l.Berenberg.civ@mail.mil

Jeffrey L. Berenberg
Principal Investigator

University of Hawaii Cancer Center

Jeffrey L. Berenberg
Ph: 808-586-2979
Email: Jeffrey.l.Berenberg.civ@mail.mil

Jeffrey L. Berenberg
Principal Investigator

Lihue

Wilcox Memorial Hospital and Kauai Medical Clinic

Jeffrey L. Berenberg
Ph: 808-586-2979
Email: Jeffrey.l.Berenberg.civ@mail.mil

Jeffrey L. Berenberg
Principal Investigator

Idaho
Boise

Saint Alphonsus Cancer Care Center-Boise

Christopher M. Reynolds
Ph: 734-712-4673
Email: christopher_reynolds@ihacares.com

Christopher M. Reynolds
Principal Investigator

Illinois
Bloomington

Illinois CancerCare-Bloomington

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Saint Joseph Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Canton

Illinois CancerCare-Canton

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Carbondale

Memorial Hospital of Carbondale

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Carthage

Illinois CancerCare-Carthage

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Centralia

Centralia Oncology Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Decatur

Cancer Care Center of Decatur

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Decatur Memorial Hospital

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Effingham

Crossroads Cancer Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Eureka

Illinois CancerCare-Eureka

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Galesburg

Illinois CancerCare-Galesburg

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Western Illinois Cancer Treatment Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Kewanee

Illinois CancerCare-Kewanee Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Macomb

Illinois CancerCare-Macomb

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Ottawa

Illinois CancerCare-Ottawa Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Pekin

Illinois CancerCare-Pekin

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Peoria

Illinois CancerCare-Peoria

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Methodist Medical Center of Illinois

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

OSF Saint Francis Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

OSF Saint Francis Radiation Oncology at Peoria Cancer Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Peru

Illinois CancerCare-Peru

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Valley Radiation Oncology

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Princeton

Illinois CancerCare-Princeton

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Rockford

SwedishAmerican Regional Cancer Center/ACT

Harvey E. Einhorn
Ph: 779-696-9400
Email: cancercare@swedishamerican.org

Harvey E. Einhorn
Principal Investigator

Springfield

Central Illinois Hematology Oncology Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Memorial Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Southern Illinois University School of Medicine

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Springfield Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Swansea

Cancer Care Specialists of Illinois-Swansea

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Indiana
Richmond

Reid Health

Howard M. Gross
Ph: 937-775-1350
Email: hgross@woh.rr.com

Howard M. Gross
Principal Investigator

Iowa
Ames

Mary Greeley Medical Center

Joseph James Merchant
Ph: 515-239-2621
Email: jjmerchant@mcfarlandclinic.com

Joseph James Merchant
Principal Investigator

McFarland Clinic PC-William R Bliss Cancer Center

Joseph James Merchant
Ph: 515-239-2621
Email: jjmerchant@mcfarlandclinic.com

Joseph James Merchant
Principal Investigator

Boone

McFarland Clinic PC-Boone

Joseph James Merchant
Ph: 515-239-2621
Email: jjmerchant@mcfarlandclinic.com

Joseph James Merchant
Principal Investigator

Clive

Medical Oncology and Hematology Associates-West Des Moines

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Mercy Cancer Center-West Lakes

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Council Bluffs

Alegent Health Mercy Hospital

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Creston

Greater Regional Medical Center

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Des Moines

Medical Oncology and Hematology Associates-Laurel

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Mercy Medical Center - Des Moines

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Fort Dodge

McFarland Clinic PC-Trinity Cancer Center

Joseph James Merchant
Ph: 515-239-2621
Email: jjmerchant@mcfarlandclinic.com

Joseph James Merchant
Principal Investigator

Jefferson

McFarland Clinic PC-Jefferson

Joseph James Merchant
Ph: 515-239-2621
Email: jjmerchant@mcfarlandclinic.com

Joseph James Merchant
Principal Investigator

Marshalltown

McFarland Clinic PC-Marshalltown

Joseph James Merchant
Ph: 515-239-2621
Email: jjmerchant@mcfarlandclinic.com

Joseph James Merchant
Principal Investigator

West Des Moines

Mercy Medical Center-West Lakes

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Kentucky
Bardstown

Flaget Memorial Hospital

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Corbin

Commonwealth Cancer Center-Corbin

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Lexington

Saint Joseph Hospital East

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Saint Joseph Radiation Oncology Resource Center

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Louisville

Jewish Hospital

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Jewish Hospital Medical Center Northeast

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Saints Mary and Elizabeth Hospital

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Shepherdsville

Jewish Hospital Medical Center South

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Louisiana
Baton Rouge

Ochsner Health Center-Summa

Robert Van Buren Emmons
Ph: 888-562-4763
Email: remmons@ochsner.org

Robert Van Buren Emmons
Principal Investigator

New Orleans

Ochsner Baptist Medical Center

Robert Van Buren Emmons
Ph: 888-562-4763
Email: remmons@ochsner.org

Robert Van Buren Emmons
Principal Investigator

Ochsner Medical Center Jefferson

Robert Van Buren Emmons
Ph: 888-562-4763
Email: remmons@ochsner.org

Robert Van Buren Emmons
Principal Investigator

Maryland
Silver Spring

Holy Cross Hospital

Frederick David Min
Ph: 310-754-7552

Frederick David Min
Principal Investigator

Massachusetts
Boston

Tufts Medical Center

Andrew M. Evens
Ph: 617-636-5000
Email: ContactUsCancerCenter@TuftsMedicalCenter.org

Andrew M. Evens
Principal Investigator

Michigan
Ann Arbor

Saint Joseph Mercy Hospital

Christopher M. Reynolds
Ph: 734-712-4673
Email: christopher_reynolds@ihacares.com

Christopher M. Reynolds
Principal Investigator

Battle Creek

Bronson Battle Creek

Kathleen J. Yost
Ph: 616-391-1230
Email: connie.szczepanek@grcop.org

Kathleen J. Yost
Principal Investigator

Dearborn

Beaumont Hospital-Dearborn

Christopher M. Reynolds
Ph: 734-712-4673
Email: christopher_reynolds@ihacares.com

Christopher M. Reynolds
Principal Investigator

Detroit

Saint John Hospital and Medical Center

Christopher M. Reynolds
Ph: 734-712-4673
Email: christopher_reynolds@ihacares.com

Christopher M. Reynolds
Principal Investigator

Flint

Genesys Hurley Cancer Institute

Christopher M. Reynolds
Ph: 734-712-4673
Email: christopher_reynolds@ihacares.com

Christopher M. Reynolds
Principal Investigator

Hurley Medical Center

Christopher M. Reynolds
Ph: 734-712-4673
Email: christopher_reynolds@ihacares.com

Christopher M. Reynolds
Principal Investigator

Grand Rapids

Mercy Health Saint Mary's

Kathleen J. Yost
Ph: 616-391-1230
Email: connie.szczepanek@grcop.org

Kathleen J. Yost
Principal Investigator

Spectrum Health at Butterworth Campus

Kathleen J. Yost
Ph: 616-391-1230
Email: connie.szczepanek@grcop.org

Kathleen J. Yost
Principal Investigator

Jackson

Allegiance Health

Christopher M. Reynolds
Ph: 734-712-4673
Email: christopher_reynolds@ihacares.com

Christopher M. Reynolds
Principal Investigator

Kalamazoo

Borgess Medical Center

Kathleen J. Yost
Ph: 616-391-1230
Email: connie.szczepanek@grcop.org

Kathleen J. Yost
Principal Investigator

West Michigan Cancer Center

Kathleen J. Yost
Ph: 616-391-1230
Email: connie.szczepanek@grcop.org

Kathleen J. Yost
Principal Investigator

Lansing

Sparrow Hospital

Christopher M. Reynolds
Ph: 734-712-4673
Email: christopher_reynolds@ihacares.com

Christopher M. Reynolds
Principal Investigator

Livonia

Saint Mary Mercy Hospital

Christopher M. Reynolds
Ph: 734-712-4673
Email: christopher_reynolds@ihacares.com

Christopher M. Reynolds
Principal Investigator

Muskegon

Mercy Health Mercy Campus

Kathleen J. Yost
Ph: 616-391-1230
Email: connie.szczepanek@grcop.org

Kathleen J. Yost
Principal Investigator

Niles

Lakeland Community Hospital

Kathleen J. Yost
Ph: 616-391-1230
Email: connie.szczepanek@grcop.org

Kathleen J. Yost
Principal Investigator

Pontiac

Saint Joseph Mercy Oakland

Christopher M. Reynolds
Ph: 734-712-4673
Email: christopher_reynolds@ihacares.com

Christopher M. Reynolds
Principal Investigator

Reed City

Spectrum Health Reed City Hospital

Kathleen J. Yost
Ph: 616-391-1230
Email: connie.szczepanek@grcop.org

Kathleen J. Yost
Principal Investigator

Saginaw

Saint Mary's of Michigan

Christopher M. Reynolds
Ph: 734-712-4673
Email: christopher_reynolds@ihacares.com

Christopher M. Reynolds
Principal Investigator

Saint Joseph

Marie Yeager Cancer Center

Kathleen J. Yost
Ph: 616-391-1230
Email: connie.szczepanek@grcop.org

Kathleen J. Yost
Principal Investigator

St. Joseph

Lakeland Hospital

Kathleen J. Yost
Ph: 616-391-1230
Email: connie.szczepanek@grcop.org

Kathleen J. Yost
Principal Investigator

Traverse City

Munson Medical Center

Kathleen J. Yost
Ph: 616-391-1230
Email: connie.szczepanek@grcop.org

Kathleen J. Yost
Principal Investigator

Warren

Saint John Macomb-Oakland Hospital

Christopher M. Reynolds
Ph: 734-712-4673
Email: christopher_reynolds@ihacares.com

Christopher M. Reynolds
Principal Investigator

Wyoming

Metro Health Hospital

Kathleen J. Yost
Ph: 616-391-1230
Email: connie.szczepanek@grcop.org

Kathleen J. Yost
Principal Investigator

Minnesota
Burnsville

Fairview Ridges Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Coon Rapids

Mercy Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Duluth

Essentia Health Cancer Center

Bret E.B. Friday
Ph: 888-203-7267
Email: bret.friday@essentiahealth.org

Bret E.B. Friday
Principal Investigator

Essentia Health Saint Mary's Medical Center

Bret E.B. Friday
Ph: 888-203-7267
Email: bret.friday@essentiahealth.org

Bret E.B. Friday
Principal Investigator

Miller-Dwan Hospital

Bret E.B. Friday
Ph: 888-203-7267
Email: bret.friday@essentiahealth.org

Bret E.B. Friday
Principal Investigator

Edina

Fairview-Southdale Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Fridley

Unity Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Maplewood

Minnesota Oncology Hematology PA-Maplewood

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Saint John's Hospital - Healtheast

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Minneapolis

Abbott-Northwestern Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Health Partners Inc

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Hennepin County Medical Center

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Robbinsdale

North Memorial Medical Health Center

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Rochester

Mayo Clinic

David J. Inwards
Ph: 855-776-0015
Email: inwards.david@mayo.edu

David J. Inwards
Principal Investigator

Saint Louis Park

Park Nicollet Clinic - Saint Louis Park

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Saint Paul

Regions Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

United Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Shakopee

Saint Francis Regional Medical Center

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Waconia

Ridgeview Medical Center

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Willmar

Rice Memorial Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Woodbury

Minnesota Oncology and Hematology PA-Woodbury

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Missouri
Bonne Terre

Parkland Health Center-Bonne Terre

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Cape Girardeau

Saint Francis Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Southeast Cancer Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Jefferson City

Capital Region Medical Center-Goldschmidt Cancer Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Saint Louis

Missouri Baptist Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Washington University School of Medicine

Brad S. Kahl
Ph: 800-600-3606
Email: info@siteman.wustl.edu

Brad S. Kahl
Principal Investigator

Sainte Genevieve

Sainte Genevieve County Memorial Hospital

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Sullivan

Missouri Baptist Sullivan Hospital

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Sunset Hills

Missouri Baptist Outpatient Center-Sunset Hills

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Montana
Billings

Montana Cancer Consortium NCORP

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Nebraska
Grand Island

CHI Health Saint Francis

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Kearney

CHI Health Good Samaritan

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Heartland Hematology and Oncology

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Lincoln

Saint Elizabeth Regional Medical Center

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Omaha

Alegent Health Bergan Mercy Medical Center

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Alegent Health Immanuel Medical Center

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Alegent Health Lakeside Hospital

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Creighton University Medical Center

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Hemotology and Oncology Consultants PC

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Papillion

Midlands Community Hospital

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

New Jersey
East Orange

Veterans Adminstration New Jersey Health Care System

Victor Tsu-Shih Chang
Ph: 800-475-2336
Email: patricia.goyer@med.va.gov

Victor Tsu-Shih Chang
Principal Investigator

New York
Auburn

Hematology Oncology Associates of Central New York-Auburn

Jeffrey J. Kirshner
Ph: 315-472-7504
Email: JKIRSHNER@HOACNY.COM

Jeffrey J. Kirshner
Principal Investigator

East Syracuse

Hematology Oncology Associates of Central New York-East Syracuse

Jeffrey J. Kirshner
Ph: 315-472-7504
Email: JKIRSHNER@HOACNY.COM

Jeffrey J. Kirshner
Principal Investigator

Rochester

University of Rochester

Jonathan Willmann Friedberg
Ph: 585-275-5830
Email: jonathan_friedberg@urmc.rochester.edu

Jonathan Willmann Friedberg
Principal Investigator

Syracuse

Hematology Oncology Associates of Central New York-Onondaga Hill

Jeffrey J. Kirshner
Ph: 315-472-7504
Email: JKIRSHNER@HOACNY.COM

Jeffrey J. Kirshner
Principal Investigator

North Carolina
Hendersonville

Hendersonville Hematology and Oncology at Pardee

James Earl Radford
Ph: 828-696-4716
Email: james.radford@pardeehospital.org

James Earl Radford
Principal Investigator

Margaret R Pardee Memorial Hospital

James Earl Radford
Ph: 828-696-4716
Email: james.radford@pardeehospital.org

James Earl Radford
Principal Investigator

Winston-Salem

Wake Forest University Health Sciences

Zanetta Stewart Lamar
Ph: 336-713-6771
Email: zlamar@wakehealth.edu

Zanetta Stewart Lamar
Principal Investigator

Ohio
Akron

Summa Akron City Hospital/Cooper Cancer Center

Jennifer Eileen Payne
Ph: 330-375-6101
Email: paynej@summahealth.org

Jennifer Eileen Payne
Principal Investigator

Barberton

Summa Barberton Hospital

Jennifer Eileen Payne
Ph: 330-375-6101
Email: paynej@summahealth.org

Jennifer Eileen Payne
Principal Investigator

Beachwood

Cleveland Clinic Cancer Center Beachwood

Anjali S. Advani
Ph: 866-223-8100
Email: advania@ccf.org

Anjali S. Advani
Principal Investigator

Centerville

Dayton Physicians LLC-Miami Valley South

Howard M. Gross
Ph: 937-775-1350
Email: hgross@woh.rr.com

Howard M. Gross
Principal Investigator

Cincinnati

Bethesda North Hospital

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Good Samaritan Hospital - Cincinnati

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Oncology Hematology Care Inc - Kenwood

Howard M. Gross
Ph: 937-775-1350
Email: hgross@woh.rr.com

Howard M. Gross
Principal Investigator

TriHealth Cancer Institute-Anderson

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

TriHealth Cancer Institute-Westside

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

University of Cincinnati

Stephen C. Medlin
Ph: 513-558-4553
Email: uchealthnews@uc.edu

Stephen C. Medlin
Principal Investigator

Cleveland

Cleveland Clinic Cancer Center/Fairview Hospital

Anjali S. Advani
Ph: 866-223-8100
Email: advania@ccf.org

Anjali S. Advani
Principal Investigator

Cleveland Clinic Foundation

Anjali S. Advani
Ph: 866-223-8100
Email: advania@ccf.org

Anjali S. Advani
Principal Investigator

Dayton

Dayton Physicians LLC-Samaritan North

Howard M. Gross
Ph: 937-775-1350
Email: hgross@woh.rr.com

Howard M. Gross
Principal Investigator

Good Samaritan Hospital - Dayton

Howard M. Gross
Ph: 937-775-1350
Email: hgross@woh.rr.com

Howard M. Gross
Principal Investigator

Miami Valley Hospital

Howard M. Gross
Ph: 937-775-1350
Email: hgross@woh.rr.com

Howard M. Gross
Principal Investigator

Samaritan North Health Center

Howard M. Gross
Ph: 937-775-1350
Email: hgross@woh.rr.com

Howard M. Gross
Principal Investigator

Findlay

Armes Family Cancer Center

Howard M. Gross
Ph: 937-775-1350
Email: hgross@woh.rr.com

Howard M. Gross
Principal Investigator

Blanchard Valley Hospital

Howard M. Gross
Ph: 937-775-1350
Email: hgross@woh.rr.com

Howard M. Gross
Principal Investigator

Orion Cancer Care

Howard M. Gross
Ph: 937-775-1350
Email: hgross@woh.rr.com

Howard M. Gross
Principal Investigator

Franklin

Atrium Medical Center-Middletown Regional Hospital

Howard M. Gross
Ph: 937-775-1350
Email: hgross@woh.rr.com

Howard M. Gross
Principal Investigator

Dayton Physicians LLC-Atrium

Howard M. Gross
Ph: 937-775-1350
Email: hgross@woh.rr.com

Howard M. Gross
Principal Investigator

Greenville

Dayton Physicians LLC-Wayne

Howard M. Gross
Ph: 937-775-1350
Email: hgross@woh.rr.com

Howard M. Gross
Principal Investigator

Wayne Hospital

Howard M. Gross
Ph: 937-775-1350
Email: hgross@woh.rr.com

Howard M. Gross
Principal Investigator

Independence

Cleveland Clinic Cancer Center Independence

Anjali S. Advani
Ph: 866-223-8100
Email: advania@ccf.org

Anjali S. Advani
Principal Investigator

Kettering

Greater Dayton Cancer Center

Howard M. Gross
Ph: 937-775-1350
Email: hgross@woh.rr.com

Howard M. Gross
Principal Investigator

Kettering Medical Center

Howard M. Gross
Ph: 937-775-1350
Email: hgross@woh.rr.com

Howard M. Gross
Principal Investigator

Mansfield

Cleveland Clinic Cancer Center Mansfield

Anjali S. Advani
Ph: 866-223-8100
Email: advania@ccf.org

Anjali S. Advani
Principal Investigator

Mayfield Heights

Hillcrest Hospital Cancer Center

Anjali S. Advani
Ph: 866-223-8100
Email: advania@ccf.org

Anjali S. Advani
Principal Investigator

Middletown

Dayton Physicians LLC-Signal Point

Howard M. Gross
Ph: 937-775-1350
Email: hgross@woh.rr.com

Howard M. Gross
Principal Investigator

Sandusky

North Coast Cancer Care

Anjali S. Advani
Ph: 866-223-8100
Email: advania@ccf.org

Anjali S. Advani
Principal Investigator

Sidney

Dayton Physicians LLC-Wilson

Howard M. Gross
Ph: 937-775-1350
Email: hgross@woh.rr.com

Howard M. Gross
Principal Investigator

Springfield

Springfield Regional Cancer Center

Howard M. Gross
Ph: 937-775-1350
Email: hgross@woh.rr.com

Howard M. Gross
Principal Investigator

Springfield Regional Medical Center

Howard M. Gross
Ph: 937-775-1350
Email: hgross@woh.rr.com

Howard M. Gross
Principal Investigator

Strongsville

Cleveland Clinic Cancer Center Strongsville

Anjali S. Advani
Ph: 866-223-8100
Email: advania@ccf.org

Anjali S. Advani
Principal Investigator

Troy

Dayton Physicians LLC-Upper Valley

Howard M. Gross
Ph: 937-775-1350
Email: hgross@woh.rr.com

Howard M. Gross
Principal Investigator

Upper Valley Medical Center

Howard M. Gross
Ph: 937-775-1350
Email: hgross@woh.rr.com

Howard M. Gross
Principal Investigator

Warrensville Heights

South Pointe Hospital

Anjali S. Advani
Ph: 866-223-8100
Email: advania@ccf.org

Anjali S. Advani
Principal Investigator

Wooster

Cleveland Clinic Wooster Family Health and Surgery Center

Anjali S. Advani
Ph: 866-223-8100
Email: advania@ccf.org

Anjali S. Advani
Principal Investigator

Oregon
Portland

Oregon Health and Science University

Stephen E.F. Spurgeon
Ph: 503-494-1080
Email: trials@ohsu.edu

Stephen E.F. Spurgeon
Principal Investigator

Pennsylvania
Philadelphia

Fox Chase Cancer Center

Henry Chi Hang Fung
Ph: 215-728-4790
Email: henry.fung@tuhs.temple.edu

Henry Chi Hang Fung
Principal Investigator

Pottstown

Pottstown Memorial Medical Center

Wei (Frank) Song
Ph: 610-327-7544
Email: frank_song@chs.net

Wei (Frank) Song
Principal Investigator

West Reading

Reading Hospital

Terrence Paul Cescon
Ph: 610-988-9323
Email: terrence.cescon@readinghealth.org

Terrence Paul Cescon
Principal Investigator

South Carolina
Gaffney

Gibbs Cancer Center-Gaffney

Asim Ranjan Pati
Ph: 800-486-5941
Email: apati@gibbscc.org

Asim Ranjan Pati
Principal Investigator

Greer

Gibbs Cancer Center-Pelham

Asim Ranjan Pati
Ph: 800-486-5941
Email: apati@gibbscc.org

Asim Ranjan Pati
Principal Investigator

Spartanburg

Spartanburg Medical Center

Asim Ranjan Pati
Ph: 800-486-5941
Email: apati@gibbscc.org

Asim Ranjan Pati
Principal Investigator

Tennessee
Chattanooga

Memorial Hospital

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Hixson

Pulmonary Medicine Center of Chattanooga-Hixson

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Ooltewah

Memorial GYN Plus

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Virginia
Charlottesville

University of Virginia Cancer Center

Michael E. Williams
Ph: 434-243-6322
Email: JME3D@hscmail.mcc.virginia.edu

Michael E. Williams
Principal Investigator

Martinsville

Memorial Hospital Of Martinsville

Sreedhar Katragadda
Ph: 276-666-7827
Email: sreedhar.katragadda@lpnt.net

Sreedhar Katragadda
Principal Investigator

Richmond

Virginia Commonwealth University/Massey Cancer Center

Victor Youssef Yazbeck
Ph: 804-628-1939
Email: vyyazbeck@vcu.edu

Victor Youssef Yazbeck
Principal Investigator

Washington
Bremerton

Harrison HealthPartners Hematology and Oncology-Bremerton

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Harrison Medical Center

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Burien

Highline Medical Center-Main Campus

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Enumclaw

Saint Elizabeth Hospital

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Federal Way

Saint Francis Hospital

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Kennewick

Kadlec Clinic Hematology and Oncology

Brian Gerald Till
Ph: 800-422-6237
Email: tillb@fhcrc.org

Brian Gerald Till
Principal Investigator

Kirkland

EvergreenHealth Medical Center

Brian Gerald Till
Ph: 800-422-6237
Email: tillb@fhcrc.org

Brian Gerald Till
Principal Investigator

Lakewood

Saint Clare Hospital

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Mount Vernon

Skagit Valley Hospital

Brian Gerald Till
Ph: 800-422-6237
Email: tillb@fhcrc.org

Brian Gerald Till
Principal Investigator

Skagit Valley Hospital Regional Cancer Care Center

Brian Gerald Till
Ph: 800-422-6237
Email: tillb@fhcrc.org

Brian Gerald Till
Principal Investigator

Port Angeles

Olympic Medical Center

Brian Gerald Till
Ph: 800-422-6237
Email: tillb@fhcrc.org

Brian Gerald Till
Principal Investigator

Poulsbo

Harrison HealthPartners Hematology and Oncology-Poulsbo

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Seattle

Fred Hutchinson Cancer Research Center

Brian Gerald Till
Ph: 800-422-6237
Email: tillb@fhcrc.org

Brian Gerald Till
Principal Investigator

Seattle Cancer Care Alliance

Brian Gerald Till
Ph: 800-422-6237
Email: tillb@fhcrc.org

Brian Gerald Till
Principal Investigator

University of Washington Medical Center

Brian Gerald Till
Ph: 800-422-6237
Email: tillb@fhcrc.org

Brian Gerald Till
Principal Investigator

Sequim

Olympic Medical Cancer Care Center

Brian Gerald Till
Ph: 800-422-6237
Email: tillb@fhcrc.org

Brian Gerald Till
Principal Investigator

Spokane

Cancer Care Northwest - Spokane South

Brian Gerald Till
Ph: 800-422-6237
Email: tillb@fhcrc.org

Brian Gerald Till
Principal Investigator

Cancer Care Northwest-North Spokane

Brian Gerald Till
Ph: 800-422-6237
Email: tillb@fhcrc.org

Brian Gerald Till
Principal Investigator

Cancer Care Northwest-Valley

Brian Gerald Till
Ph: 800-422-6237
Email: tillb@fhcrc.org

Brian Gerald Till
Principal Investigator

Tacoma

Franciscan Research Center-Northwest Medical Plaza

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Northwest Medical Specialties PLLC

Mehmet Sitki Copur
Ph: 800-998-2119
Email: mcopur@sfmc-gi.org

Mehmet Sitki Copur
Principal Investigator

Wenatchee

Wenatchee Valley Hospital and Clinics

Brian Gerald Till
Ph: 800-422-6237
Email: tillb@fhcrc.org

Brian Gerald Till
Principal Investigator

Wisconsin
Chippewa Falls

Marshfield Clinic-Chippewa Center

Ali W. Bseiso
Ph: 715-389-4457
Email: bseiso.ali@marshfieldclinic.org

Ali W. Bseiso
Principal Investigator

Eau Claire

Marshfield Clinic Cancer Center at Sacred Heart

Ali W. Bseiso
Ph: 715-389-4457
Email: bseiso.ali@marshfieldclinic.org

Ali W. Bseiso
Principal Investigator

Sacred Heart Hospital

Ali W. Bseiso
Ph: 715-389-4457
Email: bseiso.ali@marshfieldclinic.org

Ali W. Bseiso
Principal Investigator

La Crosse

Gundersen Lutheran Medical Center

Kurt Oettel
Ph: 608-775-2385
Email: cancerctr@gundersenhealth.org

Kurt Oettel
Principal Investigator

Marshfield

Marshfield Clinic

Ali W. Bseiso
Ph: 715-389-4457
Email: bseiso.ali@marshfieldclinic.org

Ali W. Bseiso
Principal Investigator

Saint Joseph's Hospital

Ali W. Bseiso
Ph: 715-389-4457
Email: bseiso.ali@marshfieldclinic.org

Ali W. Bseiso
Principal Investigator

Milwaukee

Froedtert and the Medical College of Wisconsin

Timothy Sean Fenske
Ph: 414-805-4380
Email: tfenske@mcw.edu

Timothy Sean Fenske
Principal Investigator

Minocqua

Marshfield Clinic-Minocqua Center

Ali W. Bseiso
Ph: 715-389-4457
Email: bseiso.ali@marshfieldclinic.org

Ali W. Bseiso
Principal Investigator

Mukwonago

D N Greenwald Center

Timothy Robert Wassenaar
Ph: 262-928-5539
Email: Chanda.miller@phci.org

Timothy Robert Wassenaar
Principal Investigator

New Richmond

Cancer Center of Western Wisconsin

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Oconomowoc

Oconomowoc Memorial Hospital-ProHealth Care Inc

Timothy Robert Wassenaar
Ph: 262-928-5539
Email: Chanda.miller@phci.org

Timothy Robert Wassenaar
Principal Investigator

Rice Lake

Lakeview Medical Center-Marshfield Clinic

Ali W. Bseiso
Ph: 715-389-4457
Email: bseiso.ali@marshfieldclinic.org

Ali W. Bseiso
Principal Investigator

Marshfield Clinic-Rice Lake Center

Ali W. Bseiso
Ph: 715-389-4457
Email: bseiso.ali@marshfieldclinic.org

Ali W. Bseiso
Principal Investigator

Stevens Point

Marshfield Clinic Cancer Care at Saint Michael's Hospital

Ali W. Bseiso
Ph: 715-389-4457
Email: bseiso.ali@marshfieldclinic.org

Ali W. Bseiso
Principal Investigator

Saint Michael's Hospital

Ali W. Bseiso
Ph: 715-389-4457
Email: bseiso.ali@marshfieldclinic.org

Ali W. Bseiso
Principal Investigator

Waukesha

UW Cancer Center at ProHealth Care

Timothy Robert Wassenaar
Ph: 262-928-5539
Email: Chanda.miller@phci.org

Timothy Robert Wassenaar
Principal Investigator

Waukesha Memorial Hospital

Timothy Robert Wassenaar
Ph: 262-928-5539
Email: Chanda.miller@phci.org

Timothy Robert Wassenaar
Principal Investigator

Wausau

Marshfield Clinic-Wausau Center

Ali W. Bseiso
Ph: 715-389-4457
Email: bseiso.ali@marshfieldclinic.org

Ali W. Bseiso
Principal Investigator

Weston

Diagnostic and Treatment Center

Ali W. Bseiso
Ph: 715-389-4457
Email: bseiso.ali@marshfieldclinic.org

Ali W. Bseiso
Principal Investigator

Marshfield Clinic - Weston Center

Ali W. Bseiso
Ph: 715-389-4457
Email: bseiso.ali@marshfieldclinic.org

Ali W. Bseiso
Principal Investigator

Saint Clare's Hospital

Ali W. Bseiso
Ph: 715-389-4457
Email: bseiso.ali@marshfieldclinic.org

Ali W. Bseiso
Principal Investigator

Wisconsin Rapids

Marshfield Clinic - Wisconsin Rapids Center

Ali W. Bseiso
Ph: 715-389-4457
Email: bseiso.ali@marshfieldclinic.org

Ali W. Bseiso
Principal Investigator

Canada

Saskatchewan
Regina

Allan Blair Cancer Centre

Haji I. Chalchal
Ph: 306-766-2213
Email: haji.chalchal@saskcancer.ca

Haji I. Chalchal
Principal Investigator

Saskatoon

Saskatoon Cancer Centre

Waleed Sabry Osman Ismail
Ph: 306-655-2914
Email: waleed.sabry@saskcancer.ca

Waleed Sabry Osman Ismail
Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifier NCT01415752

Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the ClinicalTrials.gov record via the link above for more information about participating sites.